
With RFK Jr. in Charge, Insurers Aren't Saying If They'll Cover Vaccines for Kids If Government Stops Recommending Them
For 60 years ACIP has provided vaccine guidance to the Centers for Disease Control and Prevention (CDC), including on the timing and dosage of childhood immunizations. Insurers are required to cover the cost of most jabs on the recommended schedule for children. On Wednesday June 25, ACIP announced it would review the schedule, just weeks after health secretary and longtime anti-vaccine activist Robert F. Kennedy Jr. replaced the entire committee with his own appointees.
When WIRED then asked 21 of the country's largest health insurance groups whether they would stop providing cost-free coverage of current routine immunizations in the event ACIP stops recommending them, only Blue Shield of California—a company in the Blue Cross Blue Shield Association—confirmed it would.
'As a payer our role is to ensure ongoing coverage and access to preventive, evidence-based care, including immunizations,' says company spokesperson Mark Seelig. 'Therefore, Blue Shield of California is committed to maintaining coverage of immunizations. The decision on whether to receive a vaccine is between our member and their provider.'
Other large insurers, including UnitedHealthcare (which provides coverage for 50 million people), Cigna, Kaiser Permanente, Anthem, Humana, and Centene Corporation, did not respond to requests for comment. Blue Cross Blue Shield of Michigan said it had no comment.
Most insurers that did respond said they were keeping an eye on developments in Washington, without indicating whether they would or would not cover vaccines dropped from the recommended schedule.
'Vaccines play an important role in the prevention of more serious illnesses,' says Phil Blando, a spokesperson at CVS Health, which owns the insurer Aetna. 'We are monitoring any changes the federal government makes to vaccination guidance and eligibility and will evaluate whether coverage adjustments are needed.'
Highmark Inc., part of the Blue Cross Blue Shield Association, operating in Pennsylvania, Delaware, West Virginia, and New York, is also waiting to see what decision ACIP reaches. 'We are closely monitoring the evolving vaccine discussions occurring in Washington, DC. Various vaccines and immunizations are covered under Highmark's member benefits, with any future coverage considerations to be evaluated as more information becomes available,' says spokesperson Aaron Billger.
Bryan Campen, of Health Care Service Corporation—the licensee of Blue Cross Blue Shield plans in Illinois, Montana, New Mexico, Oklahoma, and Texas—notes that no changes have yet been made to the vaccines ACIP recommends or the company's vaccine coverage, but says that the company will 'continue to monitor any activity that may impact preventive care recommendations and will communicate any changes to recommendations that may impact standard coverage of preventive services.'
Insurers had an eye on changes in ACIP guidance even before the committee announced it would revisit the schedule. 'As we navigate an evolving health care landscape, maintaining robust immunization coverage continues to be a top priority for protecting both individual and community health,' the industry's trade association, AHIP, said in a June 24 statement, the day before ACIP's announcement.
'We are committed to ongoing coverage of vaccines to ensure access and affordability for this respiratory virus season,' the statement continued. 'We encourage all Americans to talk to their health care provider about vaccines.'
ACIP made headlines in early June when RFK Jr. fired all 17 of its members and replaced them with eight new appointees. (The HHS secretary appoints the committee's members, but conventionally they serve fixed 4-year terms.) These new appointees include Retsef Levi, who has stated—in the face of scientific consensus—that mRNA vaccines are deadly, and Robert Malone, who routinely shares articles about supposed links between cancer and the Covid vaccine, which no credible research has found to exist. Neither Levi nor Malone replied to a request for comment.
Michael A. Ross, another recently appointed committee member, resigned from ACIP during a review of his financial holdings, the New York Times reported on June 24. When introducing his new ACIP appointees in a post on X earlier in June, RFK Jr. had described Ross as a faculty member at George Washington and Virginia Commonwealth universities—but spokespeople for the universities told NBC News4 that Ross had not taught at either in years. Ross did not reply to a request for comment.
The committee made news again on June 25 when, during its first meeting of the year, it announced it would form a working group to review the recommended immunization schedule for children and teens.
'The number of vaccines that our children and adolescents receive today exceed what children in most other developed nations receive, and what most of us in this room received when we [were] children,' ACIP chair Martin Kulldorff said during the meeting.
He noted that the group would examine the 'cumulative effect' of the recommended vaccine schedule, including interactions between vaccines, the total number of vaccines given, their timing, and recipients' exposure to vaccine ingredients.
But the process for adding vaccines to the schedule is already rigorous. Before a vaccine can receive FDA licensure, its manufacturer must prove it does not negatively affect the safety or immune response of other vaccines administered at the same time on the schedule, says Paul Offit, director of the Children's Hospital of Philadelphia's Vaccine Education Center.
In addition, 'the notion that these vaccines are somehow weakening your immune system or overwhelming your immune system is fanciful,' Offit says. Today, children are exposed to fewer viral or bacterial proteins in the first few years of the vaccine schedule than those in earlier generations. When Offit's parents received the smallpox vaccine, they were exposed to 200 proteins in a single shot. In contrast, the measles vaccine only contains 10.
During the meeting, Kulldorff repeated claims he made in 2024 that he was fired from Harvard because he refused to get the Covid vaccine; he and Malone have also each served as paid expert witnesses in two separate suits against Merck over the safety of the company's HPV vaccine and its mumps vaccine, respectively. Kulldorff did not reply to a request for comment.
The American Academy of Pediatrics (AAP) did not send representatives to last week's ACIP meeting, as it typically does. According to Academy president Susan Kressly, this was because the AAP believes the vaccine recommendation process lost credibility when its original membership was gutted by Kennedy.
'We won't lend our name or our expertise to a system that is being politicized at the expense of children's health,' Kressly said in a video posted online before the meeting was set to begin. The AAP did not reply to a request for comment about the video.
The most recent child immunization schedule that the AAP endorses, from November 2024, is posted on the AAP website. A newer one, posted on the CDC site, has already changed recommendations. It no longer lists as 'routine' Covid vaccines for children under 18 who are not immunocompromised, but instead lists them under vaccines recommended for 'shared clinical decision-making,' informed by 'personal preference and circumstances.' The change should not affect insurance coverage.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
40 minutes ago
- Associated Press
National Stuttering Association Brings Annual Conference to Denver
The largest annual gathering of people who stutter, families, and those who support them—bringing together 800 attendees for five days. DENVER, CO, UNITED STATES, July 3, 2025 / / -- The National Stuttering Association (NSA) is proud to present its 42nd Annual Conference, a transformative event designed to foster community for people who stutter. The event will take place from July 2 through July 6 at the Sheraton Denver Downtown (1550 Court Place in Denver). This one-of-a-kind event brings together approximately 800 people who stutter, speech-language professionals, families, and advocates for five days of connection, learning, and celebration. Attendees will engage in thought-provoking panel discussions and interactive workshops that center the lived experiences of people who stutter while deepening understanding of stuttering and approaches to support. Conference highlights include sessions on: --Parents: Embracing Stuttering and Fostering Acceptance --They Hear Our Voices: For Parents Who Stutter --HeardAI: Update --Teens: Just for Girls (Sisters Who Stutter) --Teens: Just for Guys --Passing Twice: LGBTQ+ People Who Stutter --Resiliency in the Workplace for People Who Stutter --Parents: Just for Dads --Stuttering in the Military: Q&A Session --Stuttering: Strength and Black Identity --Navigating Dating as a Person Who Stutters --How to Make Small Talk Your Superpower --Teens: Speak Up – Navigating Extracurriculars with a Stutter --Parents: Confidence, Communication, and Classroom Supports --Keynote Speaker: Mitch Guerra, SURVIVOR contestant and person who stutters The National Stuttering Association is a leading voice in destigmatizing stuttering and empowering people who stutter, serving thousands of people who stutter and their families annually. Stuttering is a speech disorder involving disruptions in a person's speech. Stuttering involves repetitions or prolongations of sounds and syllables or hesitations or blocks in making voiced sounds. As a nonprofit that supports people who stutter of all ages, we know that stuttering can be about more than speech and affect more aspects of everyday life than can be seen by someone outside the stuttering community. More information about the event, including the speaker lineup and schedule of events, is available at: Members of the media are welcome to attend the conference with advance arrangements. Interview subjects can be made available. Sarah Armstrong National Stuttering Association email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Forbes
44 minutes ago
- Forbes
Four Ways To Invest In Yourself While Growing Your Business
Todd Villeneuve is managing partner at IFC National Marketing, a leading IMO for independent insurance agents and financial advisors. You're killing it, right? You meet prospects for breakfast, lunch, dinner and cocktails. You entertain and conduct business at concerts, sporting events and coffee shops. You take calls day and night, manage your marketing, write new contracts, track your sales. Business is booming. Meanwhile, you're burned out, stressed out and not sleeping well. The constant cadence of activity—while great for business—is beginning to sap your energy, fog your brain and interfere with your social life. Building a business is thrilling, but it can be all-consuming. Too often, when faced with long hours, perpetual deadlines, never-ending to-do lists and mountains of detail, entrepreneurs lose sight of their most valuable assets: good health, well-being and balance. I've found that this is a classic area where you need to 'put on your own air mask first' if you want your business and your personal life to thrive. For example, I've spent my career selling insurance and financial products. The pace can be demanding and stressful, and it's not for everyone. In fact, more than 90% of new agents quit the business within the first year. So, what's different about the 10% who succeed and achieve financial success? I've observed three characteristics that stand out among a number of successful agents: • They pay careful attention to their mental and physical health. • They prioritize social and professional interactions. • They understand the importance of balancing work with everyday life. How are well-being and business success connected? Neglecting your well-being can negatively impact business performance. For example, burnout can impair concentration, decrease motivation, reduce productivity and inhibit creativity. It can impair relationships—which are critical when you're trying to build a business—as well as increase errors and drive chronic stress, anxiety, depression, insomnia and a number of other health conditions. My advice for solopreneurs, entrepreneurs, consultants, freelancers—anyone striving to build a business—is to prioritize self-care. Self-care includes everything you do to keep yourself mentally, emotionally, physically, socially and spiritually healthy. Put it on your calendar first, because if you don't make time for self-care every day, you may be inviting burnout into your life—and into your business. Fill your tank. With all that said, burnout is not a sign of weakness: It's a signal. I invite you, encourage you, implore you to listen to that signal. Better yet, take action to prevent the signal bell from ringing in the first place. This doesn't require a wholesale shift in your lifestyle. You can slowly adjust your habits and schedule over time to reprioritize your personal health and well-being. Here are four effective ways I have found to prioritize personal wellness without disrupting the flow of your business. The benefits of physical activity are numerous, and working movement into your busy days is easier than you might think. One way that I've successfully built movement into my day is to schedule 'walk-and-talk' meetings with my team. These 30-minute telephone meetings allow me to ideate with my team (I've found that exercise fuels my creativity), answer questions about work in progress and focus on the needs of that particular employee without being distracted by my email or other activities in the office. If this isn't realistic for your business model, a five-minute walk outside or even around your building is a good place to start. Take the stairs when you can. Stretch and move your body. Dance (seriously, nobody is watching). When you're the boss, your to-do list can quickly get out of hand. One way to reduce stress and free up time in your schedule is by delegating responsibilities to your trusted team. Start by ensuring that you have the right people in the right seats. I encourage business owners, especially those looking to grow and scale their businesses, to use a framework like the Entrepreneurial Operating System (EOS) to guide them through this process. I've found that all work and no play not only makes one 'dull' but can also contribute to feelings of isolation and loneliness, exacerbate stress and anxiety, and be detrimental to the personal and professional relationships you've honed over the years. To nurture your social well-being, try blending work with play. Schedule breakfast or lunch with a client at your favorite restaurant, take a group of clients to a local sporting or cultural event or host a client appreciation dinner. You can also build rapport amongst your internal team by hosting social activities for your employees outside of the office. As often as possible, make healthy choices when it comes to your diet and your sleep habits. Whether it's drinking more water, limiting alcohol intake or eating fewer processed foods, slowly adapt your behaviors over time to incorporate choices that will fuel your body and mind, as well as potentially prevent future illnesses. You might even find that your team or select clients share the same goals as you so that you can surround yourself with support. Final Thoughts Without question, building a business is hard. The learning curve is steep, the tasks plentiful, the stress unavoidable. It's a process that demands the best of you, so make sure you're able to bring your best self to work every day by investing in yourself, your health and your well-being. Start small, keep going and don't forget to ask for help along the way. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?


Medscape
44 minutes ago
- Medscape
Neuromodulation Effective for Migraine With and Without Aura
MINNEAPOLIS — Remote electrical neuromodulation (REN) appears to be a safe and effective option for a broad range of migraine types including migraine with or without aura and chronic migraine in patients who experience pain following treatment with onabotulinumtoxinA, two new studies suggested. Results of the first study, which included more than 31,000 individuals — most with migraine with or without aura — showed that use of an REN device provided relief from pain, functional disability, and nausea within 2 hours of treatment. The second study, which included 60 participants with chronic migraine receiving onabotulinumtoxinA treatment, showed that those using the REN device experienced significantly less pain during and after the procedure compared to those using a sham device. Patients often look for nonpharmacologic options to treat migraine, such as vitamins, herbs, and chiropractic care, among other options, study investigator Alan M. Rapoport, MD, clinical professor of neurology at the David Geffen School of Medicine at UCLA, told Medscape Medical News . 'We're always looking for something non-medicinal that patients would be willing to try. It's really good to have studies that show that this works as well as, or better than, any of those things.' The findings were presented at the American Headache Society (AHS) Annual Meeting 2025. Another Treatment Option Migraine with aura affects approximately 30% of patients, and research into whether it affects severity or response to treatment is limited, the researchers noted. Nerivio (Theranica; Bridgewater, New Jersey) is FDA-cleared for use in patients as young as 8 years old for the acute and preventive treatment of migraine, including chronic migraine, in adolescents and adults. In 2021, the AHS recommended REN therapy for patients who do not respond to first-line treatments such as triptans. Using prospective, real-world data, investigators evaluated 31,715 patients who used an REN device to treat 751,404 acute migraine attacks between January 2019 and September 2024. In both groups, patients had an average age of 37.5 years, and 86.5% were women. Researchers categorized 311,394 attacks in 9491 patients as migraine with aura, while 440,010 attacks in 22,224 patients had migraine without aura. Two key endpoints were assessed — the clinical characteristics of migraine with and without aura and the treatment efficacy of REN therapy in both groups. Patients used a smartphone app linked to the REN device to report pain intensity, functional disability, and migraine-associated symptoms during the attack and again 2 hours after its onset. When comparing migraine with and without aura, researchers classified patients as symptomatic if they reported moderate or severe pain and functional disability during at least half of the treatments. Similarly, if patients reported photophobia, phonophobia, and/or nausea with a migraine attack with either migraine type at least half the time, patients would be placed in a group for that specific symptom. The researchers also evaluated pain relief, pain freedom, functional disability relief, and functional disability freedom, which was measured by a consistent positive change in symptom status for at least half of treatments at 2 hours compared with prior treatment. Compared with patients who did not experience migraine with aura, those who did were significantly younger (36.2 vs 38.0 years) and reported higher rates of moderate to severe pain (91.1% vs 82.3%) and functional disability (68.9% vs 54.8%). They also had a greater prevalence of photophobia (80.6% vs 72.2%), phonophobia (67.2% vs 58.8%), and nausea or vomiting (45.9% vs 35.6%). Growing Evidence of Efficacy Findings from both studies add to growing evidence — including a randomized, double-blind, placebo-controlled trial — supporting the effectiveness of REN for migraine pain. Migraine with aura affects about 30% of patients, but its impact on symptom severity or treatment response remains underexplored. To address this, researchers analyzed prospective, real-world data from 31,715 patients who used an REN device to treat over 750,000 migraine attacks between January 2019 and September 2024. The average patient age was 37.5 years, and 86.5% were women. Among them, 311,394 attacks in 9491 patients were classified as migraine with aura, while 440,010 attacks in 22,224 patients were without aura. Two main endpoints were assessed: clinical characteristics of migraine with vs without aura and the efficacy of REN therapy in both groups. Patients reported pain intensity, functional disability, and associated symptoms via a smartphone app during the attack and again 2 hours later. Patients were classified as symptomatic if they reported moderate or severe pain and disability in at least half of treatments. Similarly, frequent photophobia, phonophobia, or nausea placed them in symptom-specific groups. Efficacy outcomes included pain relief, pain freedom, and improvement or resolution of functional disability, all measured by consistent symptom improvement in at least half of treatments at the 2-hour mark. Compared to those without aura, patients with aura were younger (36.2 vs 38.0 years) and had higher rates of moderate to severe pain (91.1% vs 82.3%), disability (68.9% vs 54.8%), photophobia (80.6% vs 72.2%), phonophobia (67.2% vs 58.8%), and nausea/vomiting (45.9% vs 35.6%). The majority in both groups experienced pain relief (69.8% vs 67.0%) and functional disability improvement (69.7% vs 62.1%) within 2 hours. Roughly one quarter achieved pain freedom (24.8% vs 26.7%), and about one third reported complete relief from functional disability (34.3% vs 35.6%). Dramatic Improvement Of all the outcomes evaluated, only functional disability relief at 2 hours was significantly greater in the migraine with aura group compared to those without aura ( P < .001). No significant between-group differences were found for the other pain-related outcomes. Both groups also experienced similar relief from migraine-associated symptoms at 2 hours, including photophobia (32.0% vs 28.5%), phonophobia (42.8% vs 38.9%), and nausea/vomiting (63.2% vs 55.1%). Relief from nausea/vomiting was significantly greater in the aura group ( P < .001), but there were no significant differences in photophobia or phonophobia relief between the groups. Regarding safety, only 0.33% of patients reported device-related adverse events, and no serious adverse events were observed. Rapoport noted that the key takeaway is this: Although migraine with aura tends to be more severe in some respects than migraine without aura, both types showed similarly strong and dramatic improvement with treatment. OnabotulinumtoxinA was the sole FDA-approved treatment for chronic migraine for many years, and patients have frequently reported pain and anxiety linked to its use as a treatment for chronic migraine, Nan Cheng, MD, assistant professor in the Department of Neurology at the University of California, Irvine School of Medicine, told conference attendees. The PREEMPT Trial The PREEMPT protocol clinicians use for treating chronic migraine with onabotulinumtoxinA can range from 31 to 40 injections per session, she noted. 'That can really cause a lot of pain and a lot of anxiety for patients,' Cheng said, noting that there are no 'established strategies to reduce procedural pain or to reduce postinjection headache' associated with onabotulinumtoxinA treatment. For the study, Cheng and colleagues evaluated 60 patients receiving onabotulinumtoxinA treatment for chronic migraine at a single center. Participants had a mean age of 48 years; most were women (81.7%) and averaged 14.7 headache days per month. Nearly half (48.3%) had migraine with or without aura, while 46.6% reported migraine with aura only. Participants wore either an REN or sham device starting 10 minutes before treatment and removed it afterward. Pain was rated at the start, midpoint, and end of the procedure using a 0-100 visual analog scale. Follow-up calls the next day assessed postprocedure headaches and adverse events. Device use alternated between REN and sham at each treatment visit. 'In the first visit, they would undergo some baseline screening and have their Botox as per usual. In the second phase, they were randomized to either the active device or the sham device while receiving Botox. 'In phase 3, then they crossed over to the other side of their active or sham device with their Botox, so if a patient was on the active device for phase two, they would then be on the sham device for phase three,' Cheng said. REN therapy significantly reduced intraprocedure pain by 14.8 points and postprocedure pain by 18.8 points compared to the sham device ( P < .001 for both). Patients using the active device were also significantly less likely to develop postprocedure headaches (15.4% vs 54.7%) compared with a baseline rate of 39% (odds ratio, 0.28; P = .008). The study was stopped early after meeting prespecified criteria for effectiveness. Cheng noted that REN therapy proved to be safe, feasible, and effective, with a true analgesic effect beyond placebo and easy integration into clinical practice. Sham Comparison Needed Commenting on the research for Medscape Medical News , Kevin Weber, MD, MHA, assistant professor of neurology and director of the Division of Headache at The Ohio State University Neurological Institute, Columbus, Ohio, said collectively, the studies show that REN therapy can be safe, but more research is needed. 'These studies indicate that this device can be a safe treatment for migraine and also could potentially used for mitigation of Botox procedural pain,' said Weber, who was not involved in the research. However, there is a lower bar to clear for FDA granting device approvals and clearance compared to when the agency approves a pharmaceutical drug, Weber, who is also associate fellowship director of the United Council for Neurologic Subspecialties headache fellowship, added. The large sample size in the study of patients with migraine with and without aura supports broader generalizability of the findings, though it lacked a sham control. Similarly, the chronic migraine study did not assess whether participants could identify whether they received the active or sham REN device, Weber noted. He emphasized the need for further research, including larger studies incorporating both sham devices and sham testing. The study of REN therapy in chronic migraine patients receiving onabotulinumtoxinA did not assess whether participants could distinguish between the active and sham devices, Weber noted. He emphasized the need for larger studies that include both sham devices and sham controls. 'If the sham is good and a true placebo, patients guessing which treatment they received shouldn't be better than chance,' he said.